Skip to Content
Merck
  • Fluorescence visualization detection of field alterations in tumor margins of oral cancer patients.

Fluorescence visualization detection of field alterations in tumor margins of oral cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research (2006-11-24)
Catherine F Poh, Lewei Zhang, Don W Anderson, J Scott Durham, P Michele Williams, Robert W Priddy, Ken W Berean, Samson Ng, Olivia L Tseng, Calum MacAulay, Miriam P Rosin
ABSTRACT

Genetically altered cells could become widespread across the epithelium of patients with oral cancer, often in clinically and histologically normal tissue, and contribute to recurrent disease. Molecular approaches have begun to yield information on cancer/risk fields; tissue optics could further extend our understanding of alteration to phenotype as a result of molecular change. We used a simple hand-held device in the operating room to directly visualize subclinical field changes around oral cancers, documenting alteration to fluorescence. A total of 122 oral mucosa biopsies were obtained from 20 surgical specimens with each biopsy being assessed for location, fluorescence visualization (FV) status, histology, and loss of heterozygosity (LOH; 10 markers on three regions: 3p14, 9p21, and 17p13). All tumors showed FV loss (FVL). For 19 of the 20 tumors, the loss extended in at least one direction beyond the clinically visible tumor, with the extension varying from 4 to 25 mm. Thirty-two of 36 FVL biopsies showed histologic change (including 7 squamous cell carcinoma/carcinomas in situ, 10 severe dysplasias, and 15 mild/moderate dysplasias) compared with 1 of the 66 FV retained (FVR) biopsies. Molecular analysis on margins with low-grade or no dysplasia showed a significant association of LOH in FVL biopsies, with LOH at 3p and/or 9p (previously associated with local tumor recurrence) present in 12 of 19 FVL biopsies compared with 3 of 13 FVR biopsies (P=0.04). These data have, for the first time, shown that direct FV can identify subclinical high-risk fields with cancerous and precancerous changes in the operating room setting.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Petroleum ether, anhydrous
Sigma-Aldrich
Petroleum ether, ACS reagent
Sigma-Aldrich
Petroleum ether, JIS special grade, ≥90.0%
Sigma-Aldrich
Petroleum ether, SAJ first grade, ≥90.0%
Sigma-Aldrich
Petrol, SAJ first grade, ≥90.0%
Sigma-Aldrich
Petroleum ether, spectrophotometric grade
Sigma-Aldrich
Petroleum ether, ACS reagent
Sigma-Aldrich
Petroleum ether, ACS reagent
Sigma-Aldrich
Ligroin, JIS special grade, ≥90.0%
Sigma-Aldrich
Ligroin, SAJ first grade, ≥90.0%